基于 thiazole 药的新型 SGLT2 抑制剂的发现,使用虚拟查,分子对接和用于糖尿病病的分子动力学模拟
V Lone1, P Khona2, M J Umekar3
1Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara, India.
SAR and QSAR in environmental research
|November 13, 2025
概括
研究人员使用计算方法开发了一种新的非糖性-葡萄糖共运输体2 (SGLT2) 抑制剂NC-1. 这种化合物在治疗糖尿病病 (DN) 方面表现有前途,因为它提供了潜在的性益处,而没有当前葡萄糖抑制剂的副作用.
科学领域:
- 药用化学 医学化学
- 计算机化药物发现技术
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 糖尿病病 (DN) 是末期病 (ESRD) 的主要原因,目前的治疗方法有局限性.
- -葡萄糖共载体2 (SGLT2) 抑制剂提供治疗益处,但糖类形式具有不良影响.
- 需要非糖性SGLT2抑制剂, thiazole支架显示出潜力.
研究的目的:
- 通过计算方法发现新的非糖性SGLT2抑制剂.
- 确定治疗糖尿病病的有前途的候选药物.
- 设计和评估一种基于 thiazole 的新型 SGLT2 抑制剂.
主要方法:
- 开发一种基于连接体的药模型 (DDHRR_1).
- 化学图书馆的虚拟选 (药物中心,埃纳).
- 分子动力学 (MD) 模拟和对接研究,以评估化合物的稳定性和相互作用.
主要成果:
- 确定了四种潜在的抑制剂,其中olodaterol显示稳定的MD相互作用.
- 基于结构见解的新型化合物NC-1的合理设计.
- NC-1 呈现出高药体能,有利的对接能量 (-11.1 kcal/mol) 和稳定的 MD 相互作用.
结论:
- 综合计算方法在发现非糖性SGLT2抑制剂方面是有效的.
- NC-1显示出作为糖尿病病治疗剂的显著潜力.
- 对于DN治疗,NC-1的进一步开发是有必要的.
更多相关视频
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
2.1K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
905
相关概念视频
01:26Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
1.6K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570
01:28Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
01:06Oral Hypoglycemic Agents: Glinides
577
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
577